Opiant Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OPNT)

$22.63 -0.09 (-0.40 %)
(As of 02/23/2018 05:30 AM ET)
Previous Close$22.72
Today's Range$22.30 - $24.28
52-Week Range$5.00 - $51.90
Volume32,700 shs
Average Volume33,961 shs
Market Capitalization$46.80 million
P/E Ratio53.88
Dividend YieldN/A
Beta-0.38

About Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals logoOpiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:OPNT
CUSIPN/A
Phone+1-310-5985410

Debt

Debt-to-Equity RatioN/A
Current Ratio1.56%
Quick Ratio1.56%

Price-To-Earnings

Trailing P/E Ratio53.8809523809524
Forward P/E Ratio31.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.45 million
Price / Sales2.54
Cash Flow$3.01 per share
Price / Cash7.53
Book Value$2.14 per share
Price / Book10.57

Profitability

Trailing EPS$0.42
Net Income$6.58 million
Net Margins8.93%
Return on Equity42.44%
Return on Assets15.34%

Miscellaneous

Employees11
Outstanding Shares2,070,000

Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings results on Monday, December, 4th. The technology company reported ($2.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $1.58. The technology company earned $0.02 million during the quarter. Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. View Opiant Pharmaceuticals' Earnings History.

When will Opiant Pharmaceuticals make its next earnings announcement?

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Opiant Pharmaceuticals.

Who are some of Opiant Pharmaceuticals' key competitors?

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:

  • Michael J. Sinclair, Executive Chairman of the Board (Age 73)
  • Roger Crystal, President, Chief Executive Officer, Director (Age 38)
  • David D. O'Toole CPA, Chief Financial Officer (Age 58)
  • Arvind Agrawal, Executive Vice President - Medical Affairs
  • Phil Skolnick Ph.D., Chief Scientific Officer (Age 69)
  • Ann L. MacDougall, Director
  • Gabrielle Alison Silver, Director (Age 42)
  • Thomas T. Thomas, Director

Who owns Opiant Pharmaceuticals stock?

Opiant Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Spark Investment Management LLC (0.99%) and Acadian Asset Management LLC (0.37%). Company insiders that own Opiant Pharmaceuticals stock include Geoffrey Wolf, Kevin Pollack, Michael Sinclair and Roger Crystal. View Institutional Ownership Trends for Opiant Pharmaceuticals.

Who bought Opiant Pharmaceuticals stock? Who is buying Opiant Pharmaceuticals stock?

Opiant Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Spark Investment Management LLC. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Kevin Pollack, Michael Sinclair and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.

How do I buy Opiant Pharmaceuticals stock?

Shares of Opiant Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of Opiant Pharmaceuticals stock can currently be purchased for approximately $22.63.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $46.80 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $0.42 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 201 Santa Monica Blvd Ste 500, SANTA MONICA, CA 90401-2213, United States. The technology company can be reached via phone at +1-310-5985410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Opiant Pharmaceuticals (NASDAQ:OPNT) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings History and Estimates Chart

Earnings by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ OPNT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018N/AView Earnings Details
12/4/2017Q1 2018($1.19)($2.77)$0.02 millionViewN/AView Earnings Details
10/13/2017Q4 2017($0.87)($0.17)$3.77 millionViewN/AView Earnings Details
6/14/2017Q3 2017($0.82)($1.55)$0.02 millionViewN/AView Earnings Details
3/16/2017Q2 2017($0.85)$4.91$13.54 millionViewN/AView Earnings Details
12/16/2016Q1 2017($1.14)($0.30)$0.70 million$1.12 millionViewN/AView Earnings Details
10/31/2016Q4 2016($0.52)$0.10 million$0.31 millionViewN/AView Earnings Details
6/8/2016Q3 2016$0.15$2.61 millionViewN/AView Earnings Details
3/15/2016Q2 2016$1.52$6.86 millionViewN/AView Earnings Details
8/7/2012$0.19$0.21ViewN/AView Earnings Details
5/14/2012$0.20$0.21ViewN/AView Earnings Details
2/7/2012$0.29$0.26ViewN/AView Earnings Details
11/9/2011$0.24$0.24ViewN/AView Earnings Details
8/2/2011$0.15$0.21ViewN/AView Earnings Details
5/9/2011$0.19$0.20ViewN/AView Earnings Details
1/27/2011$0.16$0.23ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Opiant Pharmaceuticals (NASDAQ:OPNT) Earnings Estimates

2018 EPS Consensus Estimate: $2.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.19)($1.19)($1.19)
Q2 20181$4.33$4.33$4.33
Q3 20181($0.36)($0.36)($0.36)
Q4 20181($0.50)($0.50)($0.50)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Opiant Pharmaceuticals (NASDAQ:OPNT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 63.82%
Institutional Ownership Percentage: 3.22%
Insider Trades by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Opiant Pharmaceuticals (NASDAQ OPNT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Geoffrey WolfMajor ShareholderSell34,938$22.67$792,044.46View SEC Filing  
12/8/2017Geoffrey WolfMajor ShareholderSell2,570$30.40$78,128.00View SEC Filing  
1/17/2017Michael SinclairInsiderBuy3,500$7.01$24,535.00132,720View SEC Filing  
1/17/2017Roger CrystalCEOBuy3,475$6.99$24,290.258,475View SEC Filing  
1/13/2017Kevin PollackInsiderBuy4,820$6.98$33,643.604,820View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:30 AM
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain MedicationsAegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
finance.yahoo.com - February 22 at 8:30 AM
Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)Q2 2018 EPS Estimates for Opiant Pharmaceuticals Inc Lifted by Analyst (OPNT)
www.americanbankingnews.com - February 15 at 10:18 AM
OPNT: Developing Longer-Acting Opioid Overdose TreatmentOPNT: Developing Longer-Acting Opioid Overdose Treatment
finance.yahoo.com - February 13 at 3:50 PM
Opnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCANOpnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCAN
www.streetinsider.com - February 9 at 9:48 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:18 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid OverdoseOpiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
finance.yahoo.com - February 8 at 8:18 AM
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)
globenewswire.com - January 2 at 5:35 PM
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding WarrantsOpiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants
finance.yahoo.com - January 2 at 5:35 PM
Insider Q&A: Narcan exec talks merits of spray for overdosesInsider Q&A: Narcan exec talks merits of spray for overdoses
marketbeat.com - December 31 at 8:25 AM
Critical Contrast: BioMarin Pharmaceutical (BMRN) vs. Opiant Pharmaceuticals (OPNT)Critical Contrast: BioMarin Pharmaceutical (BMRN) vs. Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - December 27 at 10:00 AM
ValuEngine Lowers Opiant Pharmaceuticals (OPNT) to SellValuEngine Lowers Opiant Pharmaceuticals (OPNT) to Sell
www.americanbankingnews.com - December 23 at 4:14 PM
BioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head SurveyBioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head Survey
www.americanbankingnews.com - December 22 at 11:22 PM
Zacks Investment Research Brokers Raise Earnings Estimates for Opiant Pharmaceuticals Inc (OPNT)Zacks Investment Research Brokers Raise Earnings Estimates for Opiant Pharmaceuticals Inc (OPNT)
www.americanbankingnews.com - December 22 at 1:26 PM
FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)FY2018 Earnings Forecast for Opiant Pharmaceuticals Inc Issued By Zacks Investment Research (OPNT)
www.americanbankingnews.com - December 21 at 5:50 PM
Geoffrey Wolf Sells 34,938 Shares of Opiant Pharmaceuticals Inc (OPNT) StockGeoffrey Wolf Sells 34,938 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock
www.americanbankingnews.com - December 21 at 2:18 PM
OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18
finance.yahoo.com - December 20 at 4:40 PM
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid OverdoseOpiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
finance.yahoo.com - December 20 at 10:18 AM
OPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal SprayOPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal Spray
finance.yahoo.com - December 19 at 4:39 PM
Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell - NasdaqOpiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell - Nasdaq
www.nasdaq.com - December 19 at 10:17 AM
Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017
finance.yahoo.com - December 19 at 10:16 AM
Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening BellOpiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell
finance.yahoo.com - December 19 at 10:16 AM
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin VaccineOpiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
finance.yahoo.com - December 18 at 10:37 AM
Opiant Pharmaceuticals (OPNT) Downgraded by TheStreetOpiant Pharmaceuticals (OPNT) Downgraded by TheStreet
www.americanbankingnews.com - December 14 at 12:34 AM
Opiant Pharmaceuticals Inc (OPNT) Major Shareholder Geoffrey Wolf Sells 2,570 SharesOpiant Pharmaceuticals Inc (OPNT) Major Shareholder Geoffrey Wolf Sells 2,570 Shares
www.americanbankingnews.com - December 12 at 6:06 PM
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017
finance.yahoo.com - December 7 at 10:34 AM
KalVista Pharmaceuticals (KALV) versus Opiant Pharmaceuticals (OPNT) Head to Head SurveyKalVista Pharmaceuticals (KALV) versus Opiant Pharmaceuticals (OPNT) Head to Head Survey
www.americanbankingnews.com - December 5 at 1:28 PM
Opiant Pharmaceuticals (OPNT) Releases Quarterly  Earnings ResultsOpiant Pharmaceuticals (OPNT) Releases Quarterly Earnings Results
www.americanbankingnews.com - December 5 at 11:08 AM
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial ResultsOpiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - December 4 at 4:41 PM
Opiant Pharmaceuticals (OPNT) Downgraded by ValuEngine to HoldOpiant Pharmaceuticals (OPNT) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - December 2 at 10:36 PM
TheStreet Lowers Opiant Pharmaceuticals (OPNT) to C+TheStreet Lowers Opiant Pharmaceuticals (OPNT) to C+
www.americanbankingnews.com - November 28 at 7:12 PM
Critical Review: ChemoCentryx (CCXI) vs. Opiant Pharmaceuticals (OPNT)Critical Review: ChemoCentryx (CCXI) vs. Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - November 8 at 5:31 PM
Zacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (OPNT) Will Post Earnings of -$1.19 Per ShareZacks: Brokerages Expect Opiant Pharmaceuticals, Inc. (OPNT) Will Post Earnings of -$1.19 Per Share
www.americanbankingnews.com - October 29 at 3:32 AM
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency - Benzinga22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency - Benzinga
www.benzinga.com - October 28 at 11:38 AM
A Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trumps Opioid DeclarationA Look At Opiant Pharmaceuticals, The Stock That Skyrocketed On Trump's Opioid Declaration
www.benzinga.com - October 27 at 9:12 AM
Comparing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)Comparing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - October 25 at 4:12 PM
Opiant Pharmaceuticals, Inc. (OPNT) Rating Increased to Strong-Buy at ValuEngineOpiant Pharmaceuticals, Inc. (OPNT) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - October 21 at 10:40 AM
FY2018 EPS Estimates for Opiant Pharmaceuticals, Inc. (OPNT) Decreased by AnalystFY2018 EPS Estimates for Opiant Pharmaceuticals, Inc. (OPNT) Decreased by Analyst
www.americanbankingnews.com - October 19 at 2:28 PM
Analysts Issue Forecasts for Opiant Pharmaceuticals, Inc.s Q1 2018 Earnings (OPNT)Analysts Issue Forecasts for Opiant Pharmaceuticals, Inc.'s Q1 2018 Earnings (OPNT)
www.americanbankingnews.com - October 18 at 11:30 AM
Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017
finance.yahoo.com - October 18 at 8:02 AM
OPNT: Looking to Keep Momentum Going into Fiscal 2018OPNT: Looking to Keep Momentum Going into Fiscal 2018
finance.yahoo.com - October 17 at 5:30 AM
Critical Review: Kadmon Holdings (KDMN) & Opiant Pharmaceuticals (OPNT)Critical Review: Kadmon Holdings (KDMN) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - October 15 at 12:22 PM
Opiant Pharmaceuticals, Inc. (OPNT) Announces Quarterly  Earnings ResultsOpiant Pharmaceuticals, Inc. (OPNT) Announces Quarterly Earnings Results
www.americanbankingnews.com - October 14 at 10:00 AM
Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio?
finance.yahoo.com - October 14 at 6:29 AM
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - October 13 at 7:46 AM
Opiant Pharmaceuticals, Inc. (OPNT) Expected to Post Earnings of -$0.87 Per ShareOpiant Pharmaceuticals, Inc. (OPNT) Expected to Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - October 9 at 10:22 PM
Reviewing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)Reviewing Opiant Pharmaceuticals (OPNT) and Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - October 8 at 12:22 AM
Opiant Pharmaceuticals (OPNT) and Strongbridge Biopharma PLC (SBBP) Head to Head ReviewOpiant Pharmaceuticals (OPNT) and Strongbridge Biopharma PLC (SBBP) Head to Head Review
www.americanbankingnews.com - October 4 at 10:26 PM
Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder ... - GlobeNewswire (press release)Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder ... - GlobeNewswire (press release)
globenewswire.com - October 2 at 8:44 PM
Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to Presidents Commission on Combating Drug Addiction and the Opioid CrisisOpiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis
finance.yahoo.com - October 1 at 6:11 PM

SEC Filings

Opiant Pharmaceuticals (NASDAQ:OPNT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Opiant Pharmaceuticals (NASDAQ:OPNT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Opiant Pharmaceuticals (NASDAQ OPNT) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.